Trailing-twelve-month (TTM) revenue is $182.59 Million with a year-over-year growth of (20.10%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $47,561,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q2 FY2026Period ended 2025-12-31 | $48,931,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-04 |
| Q3 FY2026Period ended 2026-03-31 | $43,716,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q4 FY2026Period ended 2026-06-30 | $42,378,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-27 |
| TTM revenue | $182,586,000 |
Current P/S: $76,830,356 market capitalization ÷ $182,586,000 TTM revenue = 0.42x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:35:18.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $42.38M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:43:20.460Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| LifeVantage TrueScience Skin Care Regimen | $23M | $23M | $49M | $56M | $56M | N/A |
| Product and Service, Other | $47M | $48M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Americas | $155M | $138M | $155M | $153M | N/A | N/A |
| Asia Pacific And Europe | $66M | $68M | $58M |
$182.59M
$182.59 Million
(20.10%)
vs. $228.52M a year ago (TTM)
(3.68%)
5 Year compound annual growth rate
1 Year
(20.10%)
3 Year
(5.06%)
5 Year
(3.68%)
10 Year
(1.23%)
15 Year
+10.85%
20 Year
+17.57%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $182.59M | ($45.94M) | (20.10%) |
| 2025 | $228.53M | +$28.37M | +14.17% |
| 2024 | $200.16M | ($13.23M) | (6.20%) |
| 2023 | $213.40M | +$7.04M | +3.41% |
| 2022 | $206.36M | ($13.82M) | (6.28%) |
| 2021 |
TTM Growth
(20.10%)
3-Year CAGR
(5.06%)
5-Year CAGR
(3.68%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:43:20.460Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $40M |
| $6M |
| $4M |
| Protandim | $150M | $136M | $120M | $104M | $95M | $82M |
|---|
| N/A |
| N/A |
| JAPAN | $41M | $37M | $32M | $27M | $25M | $24M |
|---|
| Non-US | N/A | N/A | N/A | N/A | $50M | $47M |
|---|
| Other Foreign | N/A | N/A | N/A | N/A | $25M | $23M |
|---|
| UNITED STATES | $145M | $131M | $149M | $146M | $178M | $135M |
|---|
| $220.18M |
| ($12.73M) |
| (5.47%) |
| 2020 | $232.91M | +$6.96M | +3.08% |
| 2019 | $225.96M | +$22.75M | +11.20% |
| 2018 | $203.20M | +$3.71M | +1.86% |
| 2017 | $199.49M | ($7.05M) | (3.41%) |
